Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants

被引:17
作者
Humar, A
Wood, S
Lipton, J
Messner, H
Meharchand, J
McGeer, A
MacDonald, K
Mazzulli, T
机构
[1] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada
[2] Princess Margaret Hosp, Dept Med, Toronto, ON, Canada
[3] Univ Toronto, Toronto, ON, Canada
关键词
D O I
10.1086/514569
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The effect of cytomegalovirus (CMV) infection on 1-year mortality rates among allogeneic bone marrow transplant recipients who are receiving a standard protocol as prophylaxis for CMV infection is unclear. We determined the risk factors for death within 1 year among 103 bone marrow transplant recipients by performing a multivariate analysis. The results of donor and recipient CMV-serologies did not predict 1-year mortality, although there was a trend towards higher mortality among CMV seropositive recipients who received marrow from seronegative donors (P = .077). Multivariate analysis revealed that the factors independently associated with 1-year mortality were the development of CMV antigenemia (relative risk [RR] = 2.74; confidence interval [CI] = 1.28-5.86), bone marrow transplantation (BMT) from unrelated donors (RR = 3.20; CI = 1.30-7.92), and severe acute graft-versus-host disease (RR = 3.50; CI = 1.50-8.17). Although significant on univariate analysis, advanced underlying disease before BMT and the development of active CMV disease after BMT were not independent risk factors. In conclusion, the development of CMV antigenemia after BMT was associated with increased I-year mortality, while the development of active CMV disease was not. Reactivation of CMV infection may represent a marker of poor immune reconstitution or may contribute to further immunosuppression after BMT.
引用
收藏
页码:606 / 610
页数:5
相关论文
共 21 条
[1]  
BACIGALUPO A, 1995, BONE MARROW TRANSPL, V16, P155
[2]   Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome [J].
Bensinger, WI ;
Buckner, CD ;
Anasetti, C ;
Clift, R ;
Storb, R ;
Barnett, T ;
Chauncey, T ;
Shulman, H ;
Appelbaum, FR .
BLOOD, 1996, 88 (07) :2787-2793
[3]   Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients [J].
Falagas, ME ;
Syndman, DR ;
Griffith, J ;
Ruthazer, R ;
Werner, BG ;
Rohrer, R ;
Freeman, R ;
Fairchild, R ;
Fawaz, K ;
Hoffman, MA ;
Kaplan, M ;
Gill, M ;
Rubin, RH ;
Dienstag, JL ;
Doran, M ;
ORourke, E ;
Vacanti, J ;
Jenkins, R ;
Lewis, WD ;
Hammer, S ;
Martin, M ;
Grady, GF ;
Leszczynski, J ;
Dougherty, N ;
Katz, A ;
Fausett, G ;
Platt, R ;
Cheeseman, SH ;
Pasternack, M ;
Gorbach, SL .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (04) :275-+
[4]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[5]   STRATEGIES FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
BOECKH, M ;
BOWDEN, R .
CLINICAL INFECTIOUS DISEASES, 1994, 19 (02) :287-298
[6]  
GROB JP, 1987, LANCET, V1, P774
[7]  
HIBBERD PL, 1995, INFECT DIS CLIN N AM, V9, P863
[8]   A RETROSPECTIVE ANALYSIS OF THE LONG-TERM EFFECT OF SPLENECTOMY ON LATE INFECTIONS, GRAFT-VERSUS-HOST DISEASE, RELAPSE, AND SURVIVAL AFTER ALLOGENEIC MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].
KALHS, P ;
SCHWARZINGER, I ;
ANDERSON, G ;
MORI, M ;
CLIFT, RA ;
STORB, R ;
BUCKNER, CD ;
APPELBAUM, FR ;
HANSEN, JA ;
SULLIVAN, KM .
BLOOD, 1995, 86 (05) :2028-2032
[9]   Evaluation of the digene hybrid capture system for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients [J].
Mazzulli, T ;
Wood, S ;
Chua, R ;
Walmsley, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (12) :2959-2962
[10]   RISK-FACTORS FOR CYTOMEGALOVIRUS-INFECTION AFTER HUMAN MARROW TRANSPLANTATION [J].
MEYERS, JD ;
FLOURNOY, N ;
THOMAS, ED .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (03) :478-488